This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PATH SHAREHOLDER ALERT: The Law Firm Of Wohl & Fruchter Is Investigating The Acquisition Of NuPathe, Inc. By Endo Health Solutions Inc.

The law firm of Wohl & Fruchter LLP is investigating the acquisition of NuPathe, Inc. (NuPathe) (Nasdaq:PATH) by Endo Health Solutions Inc. (Endo).

On December 16, 2013, NuPathe announced that Endo has agreed to commence a tender offer to purchase all of the outstanding shares of NuPathe common stock at a price of $2.85 per share, plus contractual rights to receive up to an additional $3.15 per share in contingent cash consideration payments, which will be payable upon achieving certain net sales milestones of Zecuity®, NuPathe’s FDA-approved migraine treatment. Zecuity® is the first and only FDA-approved prescription migraine patch.

Wohl & Fruchter’s investigation concerns the adequacy of the consideration being paid to PATH shareholders given the commercial potential of Zecuity®, and whether the board of directors of Nupathe breached their fiduciary duties to PATH shareholders by failing to adequately shop the company.

Persons with relevant information, and PATH shareholders with questions about this investigation, are invited to contact our Firm by calling 866.833.6245, or contacting the attorney below.

Additional information is available at  http://www.wohlfruchter.com/cases/path.

About Wohl & Fruchter

Wohl & Fruchter LLP represents plaintiffs in litigation arising from fraud and other fiduciary breaches by corporate managers, as well as other complex litigation matters. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.

This release may be deemed to constitute attorney advertising.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs